The Digest’s 2026 Multi-Slide Guide to Novonesis

Following its January 2024 creation, Novonesis unveiled its “Strategy 2030,” targeting 6–9% organic sales CAGR and an adjusted EBITDA margin of approximately 39% by the end of the decade. The company is expanding beyond its core 20 billion EUR playing field into a broader 60 billion EUR biosolutions market. Key growth drivers include investments in specialized nutrition proteins, biopharma processing aids, and sustainable aviation fuels, supported by a structured innovation pipeline and aggressive advocacy to shape global policy.